Overview

ten23 health was founded in 2021 and is a development, manufacturing and testing company for biotech start-ups and the established pharmaceutical industry.

Headquartered in Basel, Switzerland, ten23 health’s core service offering includes formulation development, drug product development and manufacturing, as well as testing services for sterile pharmaceutical products. These high-value services are critical to helping pharma and biotech customers turn a scientific concept and therapeutic modality into a viable sterile medicine that is optimised for manufacturability, patient access and ease of administration, and logistical favourability.

ten23 health embeds fairstainability in all its practices and decisions and puts the focus on people - customers, employees, patients - and the planet. The company aims for a net zero emissions target from inception, exhibiting its patient-centricity not only in the quality of service that it delivers, but also in its sustainability focus.

Highlights

• Partnering with a highly experienced team of experts, including Prof. Dr Hanns Christian Mahler, with a proven track record in pharmaceutical product design and development
• As drug development activities across biologics modalities continue to accelerate, small biotechs and large pharma companies will increasingly outsource key services which require unique and market tested expertise
• ten23 health will deliver services in an engrained, fair and sustainable manner, respecting the future of the planet and people’s health
• Supported ten23’s acquisition of swissfillon, a leader in the sterile filling of complex pharmaceuticals into innovative containers and devices, creating a vertically integrated CDMO with ten23’s Basel development lab and swissfillon’s scaled fill & finish manufacturing

Regulatory information 
This transaction involved a recommendation of 3i Investments plc.